Citigroup Maintains Buy on Sana Biotechnology, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow maintains a Buy rating on Sana Biotechnology (NASDAQ:SANA) and raises the price target from $8 to $15.
August 09, 2024 | 10:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Samantha Semenkow maintains a Buy rating on Sana Biotechnology and raises the price target from $8 to $15.
The raised price target from $8 to $15 by a reputable analyst at Citigroup is a strong positive signal for investors, indicating confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100